Advertisement

Tumor Necrosis Factor Family of Ligands and Receptors in Cancer Therapy

  • Anas Younes
  • Andrea Cerutti
Part of the Cancer Drug Discovery and Development book series (CDD&D)

Abstract

The tumor necrosis factor (TNF) family members are membrane-bound and soluble proteins that play an important physiological role in lymphocyte homeostasis, immunity, inflammation, and calcium metabolism. Abnormalities in the expression or function of these ligands and their receptors have been linked to several human diseases, including autoimmunity and cancer. These observations provided the background for exploring this system to design novel treatment strategies for autoimmune diseases, bone disorders, and cancer. Because the systemic administration of some TNF family members is toxic to normal cells, only a few have a potential therapeutic value. In this concise review, we focus on the potential role of six TNF family members in cancer therapy: CD30 ligand, CD40 ligand, receptor activator of nuclear factor-κB (RANK)/RANK ligand, TNF-related apoptosis-inducing ligand (TRAIL) Apo-2L/TRAIL, BAFF, and APRIL and their receptors.

Key Words

Hodgkin TRAIL apoptosis CD30 CD40 RANK BAFF TACI IL-13 BlyS 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001; 104:487–501.PubMedCrossRefGoogle Scholar
  2. 2.
    Younes A, Kadin ME. Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy. J Clin Oncol 2003; 21:3526–3534.PubMedCrossRefGoogle Scholar
  3. 3.
    Kwon B, Youn BS, Kwon BS. Functions of newly identified members of the tumor necrosis factor receptor/ligand superfamilies in lymphocytes. Curr Opin Immunol 1999; 11:340–345.PubMedCrossRefGoogle Scholar
  4. 4.
    Inoue J, Ishida T, Tsukamoto N, et al. Tumor necrosis factor receptor-associated factor (TRAF) family: adapter proteins that mediate cytokine signaling. Exp Cell Res 2000; 254:14–24.PubMedCrossRefGoogle Scholar
  5. 5.
    McWhirter SM, Pullen SS, Werneburg BG, et al. Structural and biochemical analysis of signal transduction by the TRAF family of adapter proteins. Cold Spring Harb Symp Quant Biol 1999; 64:551–562.PubMedCrossRefGoogle Scholar
  6. 6.
    Bhardwaj A, Aggarwal BB. Receptor-mediated choreography of life and death. J Clin Immunol 2003; 23: 317–332.PubMedCrossRefGoogle Scholar
  7. 7.
    Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 2003; 3:745–756.PubMedCrossRefGoogle Scholar
  8. 8.
    Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002; 2:420–430.PubMedCrossRefGoogle Scholar
  9. 9.
    Durkop H, Latza U, Hummel M, Eitelbach F, Seed B, Stein H. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin’s disease. Cell 1992; 68: 421–427.PubMedCrossRefGoogle Scholar
  10. 10.
    Younes A, Carbone A. CD30/CD30 ligand and CD40/CD40 ligand in malignant lymphoid disorders. Int J Biol Markers 1999; 14:135–143.PubMedGoogle Scholar
  11. 11.
    Gause A, Pohl C, Tschiersch A, et al. Clinical significance of soluble CD30 antigen in the sera of patients with untreated Hodgkin’s disease. Blood 1991; 77:1983–1988.PubMedGoogle Scholar
  12. 12.
    Zinzani PL, Pileri S, Bendandi M, et al. Clinical implications of serum levels of soluble CD30 in 70 adult anaplastic large-cell lymphoma patients. J Clin Oncol 1998; 16:1532–1537.PubMedGoogle Scholar
  13. 13.
    Nadali G, Vinante F, Ambrosetti A, et al. Serum levels of soluble CD30 are elevated in the majority of untreated patients with Hodgkin’s disease and correlate with clinical features and prognosis. J Clin Oncol 1994; 12:793–797.PubMedGoogle Scholar
  14. 14.
    Younes A, Aggarwall BB. Clinical implications of the tumor necrosis factor family in benign and malignant hematologic disorders. Cancer 2003; 98:458–467.PubMedCrossRefGoogle Scholar
  15. 15.
    Smith CA, Gruss HJ, Davis T, et al. CD30 antigen, a marker for Hodgkin’s lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell 1993; 73:1349–1360.PubMedCrossRefGoogle Scholar
  16. 16.
    Pera MF, Bennett W, Cerretti DP. Expression of CD30 and CD30 ligand in cultured cell lines from human germ-cell tumors. Lab Invest 1997; 76:497–504.PubMedGoogle Scholar
  17. 17.
    Gattei V, Degan M, Gloghini A, et al. CD30 ligand is frequently expressed in human hematopoietic malignancies of myeloid and lymphoid origin. Blood 1997; 89:2048–2059.PubMedGoogle Scholar
  18. 18.
    Younes A, Consoli U, Snell V, et al. CD30 ligand in lymphoma patients with CD30+ tumors. J Clin Oncol 1997; 15:3355–3362.PubMedGoogle Scholar
  19. 19.
    Younes A, Consoli U, Zhao S, et al. CD30 ligand is expressed on resting normal and malignant human B lymphocytes. Br J Haematol 1996; 93:569–571.PubMedCrossRefGoogle Scholar
  20. 20.
    Clark EA. CD40: a cytokine receptor in search of a ligand. Tissue Antigens 1990; 36:33–36.PubMedCrossRefGoogle Scholar
  21. 21.
    Armitage RJ, Maliszewski CR, Alderson MR, Grabstein KH, Spriggs MK, Fanslow WC. CD40L: a multi-functional ligand. Semin Immunol 1993; 5:401–412.PubMedCrossRefGoogle Scholar
  22. 22.
    van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukocyte Biol 2000; 67:2–17.PubMedGoogle Scholar
  23. 23.
    Carbone A, Gloghini A. Diagnostic significance of CD40, CD40L, and CD26 expression in Hodgkin’s disease and other lymphomas. Am J Clin Pathol 1996; 105:522–523.PubMedGoogle Scholar
  24. 24.
    Carbone A, Gloghini A, Gruss HJ, Pinto A. CD40 antigen expression on Reed-Sternberg cells. A reliable diagnostic tool for Hodgkin’s disease [letter; comment]. Am J Pathol 1995; 146:780–781.PubMedGoogle Scholar
  25. 25.
    Kato K, Santana-Sahagan E, Rassenti LZ, et al. The soluble CD40 ligand sCD154 in systemic lupus erythematosus. J Clin Invest 1999; 104:947–955.PubMedGoogle Scholar
  26. 26.
    Viallard JF, Solanilla A, Gauthier B, et al. Increased soluble and platelet-associated CD40 ligand in essential thrombocythemia and reactive thrombocytosis. Blood 2002; 99:2612–2614.PubMedCrossRefGoogle Scholar
  27. 27.
    Younes A, Snell V, Consoli U, et al. Elevated levels of biologically active soluble CD40 ligand in the serum of patients with chronic lymphocytic leukaemia. Br J Haematol 1998; 100:135–141.PubMedCrossRefGoogle Scholar
  28. 28.
    Siddiqa A, Sims-Mourtada JC, Guzman-Rojas L, et al. Regulation of CD40 and CD40 ligand by the AT-hook transcription factor AKNA. Nature 2001; 410:383–387.PubMedCrossRefGoogle Scholar
  29. 29.
    Trentin L, Zambello R, Sancetta R, et al. B lymphocytes from patients with chronic lymphoproliferative disorders are equipped with different costimulatory molecules. Cancer Res 1997; 57:4940–4947.PubMedGoogle Scholar
  30. 30.
    Storz M, Zepter K, Kamarashev J, Dummer R, Burg G, Haffner AC. Coexpression of CD40 and CD40 ligand in cutaneous T-cell lymphoma (mycosis fungoides). Cancer Res 2001; 61:452–454.PubMedGoogle Scholar
  31. 31.
    Koshy M, Berger D, Crow MK. Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J Clin Invest 1996; 98:826–837.PubMedGoogle Scholar
  32. 32.
    Berner B, Wolf G, Hummel KM, Muller GA, Reuss-Borst MA. Increased expression of CD40 ligand (CD154) on CD4+ T cells as a marker of disease activity in rheumatoid arthritis. Ann Rheum Dis 2000; 59:190–195.PubMedCrossRefGoogle Scholar
  33. 33.
    Gruss HJ, Ulrich D, Braddy S, Armitage RJ, Dower SK. Recombinant CD30 ligand and CD40 ligand share common biological activities on Hodgkin and Reed-Sternberg cells. Eur J Immunol 1995; 25:2083–2089.PubMedCrossRefGoogle Scholar
  34. 34.
    Carbone A, Gloghini A, Zagonel V, et al. The expression of CD26 and CD40 ligand is mutually exclusive in human T-cell non-Hodgkin’s lymphomas/leukemias. Blood 1995; 86:4617–4626.PubMedGoogle Scholar
  35. 35.
    Carbone A, Gloghini A, Gattei V, et al. Expression of functional CD40 antigen on Reed-Sternberg cells and Hodgkin’s disease cell lines. Blood 1995; 85:780–789.PubMedGoogle Scholar
  36. 36.
    Clodi K, Asgari Z, Younes M, et al. Expression of CD40 ligand (CD154) in B and T lymphocytes of Hodgkin disease: potential therapeutic significance. Cancer 2002; 94:1–5.PubMedCrossRefGoogle Scholar
  37. 37.
    Carbone A, Gloghini A, Gruss HJ, Pinto A. CD40 ligand is constitutively expressed in a subset of T cell lymphomas and on the microenvironmental reactive T cells of follicular lymphomas and Hodgkin’s disease. Am J Pathol 1995; 147:912–922.PubMedGoogle Scholar
  38. 38.
    Molin D, Fischer M, Xiang Z, et al. Mast cells express functional CD30 ligand and are the predominant CD30L-positive cells in Hodgkin’s disease. Br J Haematol 2001; 114:616–623.PubMedCrossRefGoogle Scholar
  39. 39.
    Pinto A, Aldinucci D, Gloghini A, et al. Human eosinophils express functional CD30 ligand and stimulate proliferation of a Hodgkin’s disease cell line. Blood 1996; 88:3299–3305.PubMedGoogle Scholar
  40. 40.
    Harless Smith S, Cancro MP. BLyS: the pivotal determinant of peripheral B cell selection and lifespan. Curr Pharm Des 2003; 9:1833–1847.PubMedCrossRefGoogle Scholar
  41. 41.
    Laabi Y, Egle A, Strasser A. TNF cytokine family: more BAFF-ling complexities. Curr Biol 2001; 11: R1013–R1016.PubMedCrossRefGoogle Scholar
  42. 42.
    Schneider P, Tschopp J. BAFF and the regulation of B cell survival. Immunol Lett 2003; 88:57–62.PubMedCrossRefGoogle Scholar
  43. 43.
    Mackay F, Ambrose C. The TNF family members BAFF and APRIL: the growing complexity. Cytokine Growth Factor Rev 2003; 14:311–324.PubMedCrossRefGoogle Scholar
  44. 44.
    Gordon NC, Pan B, Hymowitz SG, et al. BAFF/BLyS receptor 3 comprises a minimal TNF receptor-like module that encodes a highly focused ligand-binding site. Biochemistry 2003; 42:5977–5983.PubMedCrossRefGoogle Scholar
  45. 45.
    Medema JP, Planelles-Carazo L, Hardenberg G, Hahne M. The uncertain glory of APRIL. Cell Death Differ 2003; 10:1121–1125.PubMedCrossRefGoogle Scholar
  46. 46.
    Gross JA, Dillon SR, Mudri S, et al. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease: impaired B cell maturation in mice lacking BLyS. Immunity 2001; 15:289–302.PubMedCrossRefGoogle Scholar
  47. 47.
    Gross JA, Johnston J, Mudri S, et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000; 404:995–999.PubMedCrossRefGoogle Scholar
  48. 48.
    Schneider K, Kothlow S, Schneider P, et al. Chicken BAFF—a highly conserved cytokine that mediates B cell survival. Int Immunol 2004; 16:139–148.PubMedCrossRefGoogle Scholar
  49. 49.
    Thompson JS, Schneider P, Kalled SL, et al. BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population. J Exp Med 2000; 192:129–135.PubMedCrossRefGoogle Scholar
  50. 50.
    Yan M, Marsters SA, Grewal IS, Wang H, Ashkenazi A, Dixit VM. Identification of a receptor for BLyS demonstrates a crucial role in humoral immunity. Nat Immunol 2000; 1:37–41.PubMedCrossRefGoogle Scholar
  51. 51.
    Mackay F, Woodcock SA, Lawton P, et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999; 190:1697–1710.PubMedCrossRefGoogle Scholar
  52. 52.
    Khare SD, Sarosi I, Xia XZ, et al. Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc Natl Acad Sci USA 2000; 97:3370–3375.PubMedCrossRefGoogle Scholar
  53. 53.
    Groom J, Kalled SL, Cutler AH, et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren’s syndrome. J Clin Invest 2002; 109:59–68.PubMedCrossRefGoogle Scholar
  54. 54.
    Zhou T, Zhang J, Carter R, Kimberly R. BLyS and B cell autoimmunity. Curr Dir Autoimmun 2003; 6: 21–37.PubMedGoogle Scholar
  55. 55.
    Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology 2001; 142:5050–5055.PubMedCrossRefGoogle Scholar
  56. 56.
    Takahashi N, Udagawa N, Suda T. A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. Biochem Biophys Res Commun 1999; 256:449–455.PubMedCrossRefGoogle Scholar
  57. 57.
    Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998; 95:3597–3602.PubMedCrossRefGoogle Scholar
  58. 58.
    Emery JG, McDonnell P, Burke MB, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998; 273:14,363–14,367.PubMedCrossRefGoogle Scholar
  59. 59.
    Degli-Esposti M. To die or not to die—the quest of the TRAIL receptors. J Leukocyte Biol 1999; 65:535–542.PubMedGoogle Scholar
  60. 60.
    Horie R, Watanabe T, Ito K, et al. Cytoplasmic aggregation of TRAF2 and TRAF5 proteins in the Hodgkin-Reed-Sternberg cells. Am J Pathol 2002; 160:1647–1654.PubMedGoogle Scholar
  61. 61.
    Boucher LM, Marengere LE, Lu Y, Thukral S, Mak TW. Binding sites of cytoplasmic effectors TRAF1, 2, and 3 on CD30 and other members of the TNF receptor superfamily. Biochem Biophys Res Commun 1997; 233:592–600.PubMedCrossRefGoogle Scholar
  62. 62.
    Duckett CS, Gedrich RW, Gilfillan MC, Thompson CB. Induction of nuclear factor kappaB by the CD30 receptor is mediated by TRAF1 and TRAF2. Mol Cell Biol 1997; 17:1535–1542.PubMedGoogle Scholar
  63. 63.
    Kieff E. Tumor necrosis factor receptor-associated factor (TRAF)-1, TRAF-2, and TRAF-3 interact in vivo with the CD30 cytoplasmic domain; TRAF-2 mediates CD30-induced nuclear factor kappa B activation. Proc Natl Acad Sci USA 1997; 94:12732.PubMedGoogle Scholar
  64. 64.
    Aizawa S, Nakano H, Ishida T, et al. Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkappaB activation. J Biol Chem 1997; 272:2042–2045.PubMedCrossRefGoogle Scholar
  65. 65.
    Ansieau S, Scheffrahn I, Mosialos G, et al. Tumor necrosis factor receptor-associated factor (TRAF)-1, TRAF-2, and TRAF-3 interact in vivo with the CD30 cytoplasmic domain; TRAF-2 mediates CD30-induced nuclear factor kappa B activation. Proc Natl Acad Sci USA 1996; 93:14,053–14,058.PubMedCrossRefGoogle Scholar
  66. 66.
    Cerutti A, Kim EC, Shah S, et al. Dysregulation of CD30+ T cells by leukemia impairs isotype switching in normal B cells. Nat Immunol 2001; 2:150–156.PubMedCrossRefGoogle Scholar
  67. 67.
    Cerutti A, Schaffer A, Goodwin RG, et al. Engagement of CD153 (CD30 ligand) by CD30+ T cells inhibits class switch DNA recombination and antibody production in human IgD+ IgM+ B cells. J Immunol 2000; 165: 786–794.PubMedGoogle Scholar
  68. 68.
    Hubinger G, Muller E, Scheffrahn I, et al. CD30-mediated cell cycle arrest associated with induced expression of p21(CIP1/WAF1) in the anaplastic large cell lymphoma cell line Karpas 299. Oncogene 2001; 20:590–598.PubMedCrossRefGoogle Scholar
  69. 69.
    Hsu PL, Hsu SM. Autocrine growth regulation of CD30 ligand in CD30-expressing Reed-Sternberg cells: distinction between Hodgkin’s disease and anaplastic large cell lymphoma. Lab Invest 2000; 80:1111–1119.PubMedGoogle Scholar
  70. 70.
    Mori M, Manuelli C, Pimpinelli N, et al. CD30-CD30 ligand interaction in primary cutaneous CD30(+) T-cell lymphomas: a clue to the pathophysiology of clinical regression. Blood 1999; 94:3077–3083.PubMedGoogle Scholar
  71. 71.
    Gruss HJ, Ulrich D, Dower SK, Herrmann F, Brach MA. Activation of Hodgkin cells via the CD30 receptor induces autocrine secretion of interleukin-6 engaging the NF-kappabeta transcription factor. Blood 1996; 87: 2443–2449.PubMedGoogle Scholar
  72. 72.
    Gruss HJ, Boiani N, Williams DE, Armitage RJ, Smith CA, Goodwin RG. Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood 1994; 83:2045–2056.PubMedGoogle Scholar
  73. 73.
    Zheng B, Fiumara P, Li YV, et al. MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. Blood 2003; 102: 1019–1027.PubMedCrossRefGoogle Scholar
  74. 74.
    Dadgostar H, Zarnegar B, Hoffmann A, et al. Cooperation of multiple signaling pathways in CD40-regulated gene expression in B lymphocytes. Proc Natl Acad Sci USA 2002; 99:1497–1502.PubMedCrossRefGoogle Scholar
  75. 75.
    Werneburg BG, Zoog SJ, Dang TT, Kehry MR, Crute JJ. Molecular characterization of CD40 signaling intermediates. J Biol Chem 2001; 276:43,334–43,342.PubMedCrossRefGoogle Scholar
  76. 76.
    Pullen SS, Dang TT, Crute JJ, Kehry MR. CD40 signaling through tumor necrosis factor receptor-associated factors (TRAFs). Binding site specificity and activation of downstream pathways by distinct TRAFs. J Biol Chem 1999; 274:14,246–14,254.PubMedCrossRefGoogle Scholar
  77. 77.
    Lomaga MA, Yeh WC, Sarosi I, et al. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev 1999; 13:1015–1024.PubMedGoogle Scholar
  78. 78.
    Lee HH, Dempsey PW, Parks TP, Zhu X, Baltimore D, Cheng G. Specificities of CD40 signaling: involvement of TRAF2 in CD40-induced NF-kappaB activation and intercellular adhesion molecule-1 up-regulation. Proc Natl Acad Sci USA 1999; 96:1421–1426.PubMedCrossRefGoogle Scholar
  79. 79.
    Kosaka Y, Calderhead DM, Manning EM, et al. Activation and regulation of the IkappaB kinase in human B cells by CD40 signaling. Eur J Immunol 1999; 29:1353–1362.PubMedCrossRefGoogle Scholar
  80. 80.
    Fiumara P, Younes A. CD40 ligand (CD154) and tumour necrosis factor-related apoptosis inducing ligand (Apo-2L) in haematological malignancies. Br J Haematol 2001; 113:265–274.PubMedCrossRefGoogle Scholar
  81. 81.
    Avery DT, Kalled SL, Ellyard JI, et al. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J Clin Invest 2003; 112:286–297.PubMedCrossRefGoogle Scholar
  82. 82.
    von Bulow GU, Bram RJ. NF-AT activation induced by a CAML-interacting member of the tumor necrosis factor receptor superfamily. Science 1997; 278:138–141.CrossRefGoogle Scholar
  83. 83.
    Xia XZ, Treanor J, Senaldi G, et al. TACI is a TRAF-interacting receptor for TALL-1, a tumor necrosis factor family member involved in B cell regulation. J Exp Med 2000; 192:137–143.PubMedCrossRefGoogle Scholar
  84. 84.
    Cancer vaccine—antigenics. BioDrugs 2002; 16:72–74.Google Scholar
  85. 85.
    Hatada EN, Do RK, Orlofsky A, et al. NF-kappa B1 p50 is required for BLyS attenuation of apoptosis but dispensable for processing of NF-kappa B2 p100 to p52 in quiescent mature B cells. J Immunol 2003; 171: 761–768.PubMedGoogle Scholar
  86. 86.
    Claudio E, Brown K, Park S, Wang H, Siebenlist U. BAFF-induced NEMO-independent processing of NF-kappa B2 in maturing B cells. Nat Immunol 2002; 3:958–965.PubMedCrossRefGoogle Scholar
  87. 87.
    Batten M, Groom J, Cachero TG, et al. BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med 2000; 192:1453–1466.PubMedCrossRefGoogle Scholar
  88. 88.
    Kayagaki N, Yan M, Seshasayee D, et al. BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2. Immunity 2002; 17:515–524.PubMedCrossRefGoogle Scholar
  89. 89.
    Thompson JS, Bixler SA, Qian F, et al. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 2001; 293:2108–2111.PubMedCrossRefGoogle Scholar
  90. 90.
    Steed PM, Hubert RS. The TNF superfamily is on the TRAIL to BlyS. Drug Discov Today 2003; 8: 114–117.PubMedCrossRefGoogle Scholar
  91. 91.
    Schneider P, MacKay F, Steiner V, et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999; 189:1747–1756.PubMedCrossRefGoogle Scholar
  92. 92.
    Harless Smith S, Cancro MP. Integrating B cell homeostasis and selection with BLyS. Arch Immunol Ther Exp (Warsz). 2003; 51:209–218.Google Scholar
  93. 93.
    Scaffidi C, Schmitz I, Krammer PH, Peter ME. The role of c-FLIP in modulation of CD95-induced apoptosis. J Biol Chem 1999; 274:1541–1548.PubMedCrossRefGoogle Scholar
  94. 94.
    Nardelli B, Belvedere O, Roschke V, et al. Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 2001; 97:198–204.PubMedCrossRefGoogle Scholar
  95. 95.
    Dejardin E, Droin NM, Delhase M, et al. The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity 2002; 17:525–535.PubMedCrossRefGoogle Scholar
  96. 96.
    Litinskiy MB, Nardelli B, Hilbert DM, et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 2002; 3:822–829.PubMedCrossRefGoogle Scholar
  97. 97.
    Wu Y, Bressette D, Carrell JA, et al. Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS. J Biol Chem 2000; 275:35,478–35,485.PubMedCrossRefGoogle Scholar
  98. 98.
    Schiemann B, Gommerman JL, Vora K, et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 2001; 293:2111–2114.PubMedCrossRefGoogle Scholar
  99. 99.
    Huard B, Schneider P, Mauri D, Tschopp J, French LE. T cell costimulation by the TNF ligand BAFF. J Immunol 2001; 167:6225–6231.PubMedGoogle Scholar
  100. 100.
    Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling [see comments]. Nature 2000; 403:503–511.PubMedCrossRefGoogle Scholar
  101. 101.
    von Bulow GU, van Deursen JM, Bram RJ. Regulation of the T-independent humoral response by TACI. Immunity 2001; 14:573–582.CrossRefGoogle Scholar
  102. 102.
    Van Kooten C, Banchereau J. CD40-CD40 ligand: a multifunctional receptor-ligand pair. Adv Immunol 1996; 61:1–77.PubMedGoogle Scholar
  103. 103.
    Hanada T, Yoshida H, Kato S, et al. Suppressor of cytokine signaling-1 is essential for suppressing dendritic cell activation and systemic autoimmunity. Immunity 2003; 19: 437–450.PubMedCrossRefGoogle Scholar
  104. 104.
    O’Connor BP, Raman VS, Erickson LD, et al. BCMA Is essential for the survival of long-lived bone marrow plasma cells. J Exp Med 2004; 199:91–98.PubMedCrossRefGoogle Scholar
  105. 105.
    Yu G, Boone T, Delaney J, et al. APRIL and TALL-I and receptors BCMA and TACI: system for regulating humoral immunity. Nat Immunol 2000; 1:252–256.PubMedCrossRefGoogle Scholar
  106. 106.
    Varfolomeev E, Kischkel F, Martin F, et al. APRIL-deficient mice have normal immune system development. Mol Cell Biol 2004; 24:997–1006.PubMedCrossRefGoogle Scholar
  107. 107.
    Kataoka T, Schroter M, Hahne M, et al. FLIP prevents apoptosis induced by death receptors but not by perforin/granzyme B, chemotherapeutic drugs, and gamma irradiation. J Immunol 1998; 161:3936–3942.PubMedGoogle Scholar
  108. 108.
    Darnay BG, Ni J, Moore PA, Aggarwal BB. Activation of NF-kappaB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-kappaB-inducing kinase. Identification of a novel TRAF6 interaction motif. J Biol Chem 1999; 274:7724–7731.PubMedCrossRefGoogle Scholar
  109. 109.
    Wong BR, Josien R, Lee SY, Vologodskaia M, Steinman RM, Choi Y. The TRAF family of signal transducers mediates NF-kappaB activation by the TRANCE receptor. J Biol Chem 1998; 273:28,355–28,359.PubMedCrossRefGoogle Scholar
  110. 110.
    Darnay BG, Haridas V, Ni J, Moore PA, Aggarwal BB. Characterization of the intracellular domain of receptor activator of NF-kappaB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappab and c-Jun N-terminal kinase. J Biol Chem 1998; 273:20,551–20,555.PubMedCrossRefGoogle Scholar
  111. 111.
    Mukhopadhyay A, Fiumara P, Li Y, Darnay BG, Aggarwal B, Younes A. Receptor activator of nuclear factor-kB (RANK) ligand activates mitogen-activated protein kinases signaling pathways in Hodgkin/Reed-Sternberg cells. Blood 2002; 99:3485–3486.Google Scholar
  112. 112.
    Fiumara P, Snell V, Li Y, et al. Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines. Blood 2001; 98:2784–2790.PubMedCrossRefGoogle Scholar
  113. 113.
    Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999; 397:315–323.PubMedCrossRefGoogle Scholar
  114. 114.
    Dougall WC, Glaccum M, Charrier K, et al. RANK is essential for osteoclast and lymph node development. Genes Dev 1999; 13:2412–2424.PubMedCrossRefGoogle Scholar
  115. 115.
    Li J, Sarosi I, Yan XQ, et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA 2000; 97: 1566–1571.PubMedCrossRefGoogle Scholar
  116. 116.
    Mizuno A, Amizuka N, Irie K, et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 1998; 247:610–615.PubMedCrossRefGoogle Scholar
  117. 117.
    Whyte MP, Obrecht SE, Finnegan PM, et al. Osteoprotegerin deficiency and juvenile Paget’s disease. N Engl J Med 2002; 347:175–184.PubMedCrossRefGoogle Scholar
  118. 118.
    Josien R, Wong BR, Li HL, Steinman RM, Choi Y. TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells. J Immunol 1999; 162:2562–2568.PubMedGoogle Scholar
  119. 119.
    Josien R, Li HL, Ingulli E, et al. TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo. J Exp Med 2000; 191:495–502.PubMedCrossRefGoogle Scholar
  120. 120.
    Kim YM, Lee YM, Kim HS, et al. TNF-related activation-induced cytokine (TRANCE) induces angiogenesis through the activation of Src and phospholipase C (PLC) in human endothelial cells. J Biol Chem 2002; 277: 6799–6805.PubMedCrossRefGoogle Scholar
  121. 121.
    Fata JE, Kong YY, Li J, et al. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 2000; 103:41–50.PubMedCrossRefGoogle Scholar
  122. 122.
    Roux S, Meignin V, Quillard J, et al. RANK (receptor activator of nuclear factor-kappaB) and RANKL expression in multiple myeloma. Br J Haematol 2002; 117:86–92.PubMedCrossRefGoogle Scholar
  123. 123.
    Pearse RN, Sordillo EM, Yaccoby S, et al. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci USA 2001; 98:11,581–11,586.PubMedCrossRefGoogle Scholar
  124. 124.
    Seidel C, Hjertner O, Abildgaard N, et al. Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. Blood 2001; 98:2269–2271.PubMedCrossRefGoogle Scholar
  125. 125.
    Lipton A, Ali SM, Leitzel K, et al. Serum osteoprotegerin levels in healthy controls and cancer patients. Clin Cancer Res 2002; 8:2306–2310.PubMedGoogle Scholar
  126. 126.
    Brown JM, Vessella RL, Kostenuik PJ, Dunstan CR, Lange PH, Corey E. Serum osteoprotegerin levels are increased in patients with advanced prostate cancer. Clin Cancer Res 2001; 7:2977–2983.PubMedGoogle Scholar
  127. 127.
    Brown JM, Corey E, Lee ZD, et al. Osteoprotegerin and rank ligand expression in prostate cancer. Urology 2001; 57:611–616.PubMedCrossRefGoogle Scholar
  128. 128.
    Cretney E, Takeda K, Yagita H, Glaccum M, Peschon JJ, Smyth MJ. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol 2002; 168:1356–1361.PubMedGoogle Scholar
  129. 129.
    Takeda K, Smyth MJ, Cretney E, et al. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med 2002; 195:161–169.PubMedCrossRefGoogle Scholar
  130. 130.
    Chou AH, Tsai HF, Lin LL, Hsieh SL, Hsu PI, Hsu PN. Enhanced proliferation and increased IFN-gamma production in T cells by signal transduced through TNF-related apoptosis-inducing ligand. J Immunol 2001; 167:1347–1352.PubMedGoogle Scholar
  131. 131.
    Choi C, Kutsch O, Park J, Zhou T, Seol DW, Benveniste EN. Tumor necrosis factor-related apoptosis-inducing ligand induces caspase-dependent interleukin-8 expression and apoptosis in human astroglioma cells. Mol Cell Biol 2002; 22:724–736.PubMedGoogle Scholar
  132. 132.
    Li JH, Kirkiles-Smith NC, McNiff JM, Pober JS. TRAIL induces apoptosis and inflammatory gene expression in human endothelial cells. J Immunol 2003; 171:1526–1533.PubMedGoogle Scholar
  133. 133.
    Schneider P, Thome M, Burns K, et al. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. Immunity 1997; 7:831–836.PubMedCrossRefGoogle Scholar
  134. 134.
    Lin Y, Devin A, Cook A, et al. The death domain kinase RIP is essential for TRAIL (Apo2L)-induced activation of IkappaB kinase and c-Jun N-terminal kinase. Mol Cell Biol 2000; 20:6638–6645.PubMedCrossRefGoogle Scholar
  135. 135.
    Green DR, Evan GI. A matter of life and death. Cancer Cell 2002; 1:19–30.PubMedCrossRefGoogle Scholar
  136. 136.
    Deng Y, Lin Y, Wu X. TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO. Genes Dev 2002; 16:33–45.PubMedCrossRefGoogle Scholar
  137. 137.
    LeBlanc H, Lawrence D, Varfolomeev E, et al. Tumor-cell resistance to death receptor—induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med 2002; 8:274–281.PubMedCrossRefGoogle Scholar
  138. 138.
    Griffith TS, Chin WA, Jackson GC, Lynch DH, Kubin MZ. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol 1998; 161:2833–2840.PubMedGoogle Scholar
  139. 139.
    Jeremias I, Kupatt C, Baumann B, Herr I, Wirth T, Debatin KM. Inhibition of nuclear factor kappaB activation attenuates apoptosis resistance in lymphoid cells. Blood 1998; 91:4624–4631.PubMedGoogle Scholar
  140. 140.
    Zhang XD, Franco A, Myers K, Gray C, Nguyen T, Hersey P. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res 1999; 59:2747–2753.PubMedGoogle Scholar
  141. 141.
    Mitsiades N, Mitsiades CS, Poulaki V, Anderson KC, Treon SP. Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells. Blood 2002; 99: 2162–2171.PubMedCrossRefGoogle Scholar
  142. 142.
    Chen X, Thakkar H, Tyan F, et al. Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene 2001; 20:6073–6083.PubMedCrossRefGoogle Scholar
  143. 143.
    Shiiki K, Yoshikawa H, Kinoshita H, et al. Potential mechanisms of resistance to TRAIL/Apo2L-induced apoptosis in human promyelocytic leukemia HL-60 cells during granulocytic differentiation. Cell Death Differ 2000; 7: 939–946.PubMedCrossRefGoogle Scholar
  144. 144.
    Fulda S, Meyer E, Debatin KM. Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene 2002; 21:2283–2294.PubMedCrossRefGoogle Scholar
  145. 145.
    Bin L, Li X, Xu LG, Shu HB. The short splice form of Casper/c-FLIP is a major cellular inhibitor of TRAIL-induced apoptosis. FEBS Lett 2002; 510:37–40.PubMedCrossRefGoogle Scholar
  146. 146.
    Lincz LF, Yeh TX, Spencer A. TRAIL-induced eradication of primary tumour cells from multiple myeloma patient bone marrows is not related to TRAIL receptor expression or prior chemotherapy. Leukemia 2001; 15: 1650–1657.PubMedCrossRefGoogle Scholar
  147. 147.
    Teitz T, Wei T, Valentine MB, et al. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN [see comments]. Nat Med 2000; 6:529–535.PubMedCrossRefGoogle Scholar
  148. 148.
    Herrnring C, Reimer T, Jeschke U, et al. Expression of the apoptosis-inducing ligands FasL and TRAIL in malignant and benign human breast tumors. Histochem Cell Biol 2000; 113:189–194.PubMedCrossRefGoogle Scholar
  149. 149.
    Nakamura M, Rieger J, Weller M, Kim J, Kleihues P, Ohgaki H. APO2L/TRAIL expression in human brain tumors. Acta Neuropathol (Berl) 2000; 99:1–6.CrossRefGoogle Scholar
  150. 150.
    Zhao S, Asgary Z, Wang Y, Goodwin R, Andreeff M, Younes A. Functional expression of TRAIL by lymphoid and myeloid tumour cells. Br J Haematol 1999; 106:827–832.PubMedCrossRefGoogle Scholar
  151. 151.
    Wahl AF, Cerveny CH, Klussman K, et al. SGN-30, a chimeric antibody to CD30, for the treatment of Hodgkin’s disease. Proc Am Assoc Cancer Res 2002; 43:4979a.Google Scholar
  152. 152.
    Kitada S, Zapata JM, Andreeff M, Reed JC. Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia. Br J Haematol 1999; 106: 995–1004.PubMedCrossRefGoogle Scholar
  153. 153.
    Romano MF, Lamberti A, Tassone P, et al. Triggering of CD40 antigen inhibits fludarabine-induced apoptosis in B chronic lymphocytic leukemia cells. Blood 1998; 92:990–995.PubMedGoogle Scholar
  154. 154.
    Ghia P, Boussiotis VA, Schultze JL, et al. Unbalanced expression of bcl-2 family proteins in follicular lymphoma: contribution of CD40 signaling in promoting survival. Blood 1998; 91:244–251.PubMedGoogle Scholar
  155. 155.
    Lomo J, Blomhoff HK, Jacobsen SE, Krajewski S, Reed JC, Smeland EB. Interleukin-13 in combination with CD40 ligand potently inhibits apoptosis in human B lymphocytes: upregulation of Bcl-xL and Mcl-1. Blood 1997; 89: 4415–4424.PubMedGoogle Scholar
  156. 156.
    Clodi K, Asgary Z, Zhao S, et al. Coexpression of CD40 and CD40 ligand in B-cell lymphoma cells. Br J Haematol 1998; 103:270–275.PubMedCrossRefGoogle Scholar
  157. 157.
    Younes A. The dynamics of life and death of malignant lymphocytes. Curr Opin Oncol 1999; 11: 364–369.PubMedCrossRefGoogle Scholar
  158. 158.
    French RR, Chan HT, Tutt AL, Glennie MJ. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat Med 1999; 5:548–553.PubMedCrossRefGoogle Scholar
  159. 159.
    Kato K, Cantwell MJ, Sharma S, Kipps TJ. Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. J Clin Invest 1998; 101:1133–1141.PubMedCrossRefGoogle Scholar
  160. 160.
    Tutt AL, O’Brien L, Hussain A, Crowther GR, French RR, Glennie MJ. T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody. J Immunol 2002; 168:2720–2728.PubMedGoogle Scholar
  161. 161.
    Vonderheide RH, Dutcher JP, Anderson JE, et al. Phase I study of recombinant human CD40 ligand in cancer patients. J Clin Oncol 2001; 19:3280–3287.PubMedGoogle Scholar
  162. 162.
    Younes A. CD40 ligand therapy of lymphoma patients. J Clin Oncol 2001; 19:4351–4353.PubMedGoogle Scholar
  163. 163.
    Wierda WG, Cantwell MJ, Woods SJ, Rassenti LZ, Prussak CE, Kipps TJ. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood 2000; 96:2917–2924.PubMedGoogle Scholar
  164. 164.
    Batten M, Fletcher C, Ng LG, et al. TNF deficiency fails to protect BAFF transgenic mice against autoimmunity and reveals a predisposition to B cell lymphoma. J Immunol 2004; 172:812–822.PubMedGoogle Scholar
  165. 165.
    Klein B, Tarte K, Jourdan M, et al. Survival and proliferation factors of normal and malignant plasma cells. Int J Hematol 2003; 78:106–113.PubMedGoogle Scholar
  166. 166.
    Kolb JP, Kern C, Quiney C, Roman V, Billard C. Re-establishment of a normal apoptotic process as a therapeutic approach in B-CLL. Curr Drug Targets Cardiovasc Haematol Disord 2003; 3:261–286.PubMedCrossRefGoogle Scholar
  167. 167.
    Novak AJ, Bram RJ, Kay NE, Jelinek DF. Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival. Blood 2002; 100:2973–2979.PubMedCrossRefGoogle Scholar
  168. 168.
    Moreaux J, Legouffe E, Jourdan E, et al. BAFF and APRIL protect myeloma cells from apoptosis induced by IL-6 deprivation and dexamethasone. Blood 2003; 103:3148–3157.PubMedCrossRefGoogle Scholar
  169. 169.
    Novak AJ, Darce JR, Arendt BK, et al. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood 2004; 103:689–694.PubMedCrossRefGoogle Scholar
  170. 170.
    He B, Raab-Traub N, Casali P, Cerutti A. EBV-encoded latent membrane protein 1 cooperates with BAFF/BLyS and APRIL to induce T cell-independent Ig heavy chain class switching. J Immunol 2003; 171:5215–5224.PubMedGoogle Scholar
  171. 171.
    Kern C, Cornuel JF, Billard C, et al. Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. Blood 2004; 103:679–688.PubMedCrossRefGoogle Scholar
  172. 172.
    Staudt LM. Gene expression profiling of lymphoid malignancies. Annu Rev Med 2002; 53:303–318.PubMedCrossRefGoogle Scholar
  173. 173.
    Abbasi. Phase I trial of fludarabine and paclitaxel in non-Hodgkin’s lymphoma. Med Oncol 2003; 20:53–58.PubMedCrossRefGoogle Scholar
  174. 174.
    Benimetskaya L, Miller P, Benimetsky S, et al. Inhibition of potentially anti-apoptotic proteins by antisense protein kinase C-alpha (Isis 3521) and antisense bcl-2 (G3139) phosphorothioate oligodeoxynucleotides: relationship to the decreased viability of T24 bladder and PC3 prostate cancer cells. Mol Pharmacol 2001; 60:1296–1307.PubMedGoogle Scholar
  175. 175.
    Croucher PI, Shipman CM, Lippitt J, et al. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 2001; 98:3534–3540.PubMedCrossRefGoogle Scholar
  176. 176.
    Nagane M, Huang HJ, Cavenee WK. The potential of TRAIL for cancer chemotherapy. Apoptosis 2001; 6:191–197.PubMedCrossRefGoogle Scholar
  177. 177.
    French LE, Tschopp J. The TRAIL to selective tumor death. Nat Med 1999; 5:146–147.PubMedCrossRefGoogle Scholar
  178. 178.
    El-Deiry WS. Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling. Cell Death Differ 2001; 8:1066–1075.PubMedCrossRefGoogle Scholar
  179. 179.
    Dobson C, Edwards BF, Main S, et al. Generation of human therapeutic anti-TRAIL-R1 agonistic antibodies by phage display. Proc Am Assoc Cancer Res 2002; 43:2869a.Google Scholar
  180. 180.
    Ichikawa K, Liu W, Zhao L, et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 2001; 7:954–960.PubMedCrossRefGoogle Scholar
  181. 181.
    Ohtsuka T, Buchsbaum D, Oliver P, Makhija S, Kimberly R, Zhou T. Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway. Oncogene 2003; 22:2034–2044.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2005

Authors and Affiliations

  • Anas Younes
    • 1
  • Andrea Cerutti
    • 1
  1. 1.Department of Lymphoma and MyelomaThe University of Texas, M. D. Anderson Cancer CenterHouston

Personalised recommendations